Skin Disease/Disorder, Hidradenitis Suppurativa
IFRXInflaRx N.V.Catalyst overview
Research summary
This catalyst tracks a Phase 2a data readout for Izicopan (C5aR Inhibitor) in Skin Disease/Disorder, Hidradenitis Suppurativa. The expected timing is based on the latest available company guidance and may change.
03/19/26:- Strong Ph2a HS data; full results at 2026 scientific meetings; Phase 2b FDA discussions ongoing. 03/30/26:- Company prioritizes FDA dermatology discussions for izicopan in HS. 05/06/26:- FDA interactions largely concluded; further HS development envisioned only with a partner. 08/06/26:- Prior Phase 2a HS activity and safety were reiterated.
Verification
Confirm timing and program details against the company announcement or filing.